Start here if you're new
what it is
West makes the stoppers, seals, and syringe parts that keep injectable drugs usable and sterile.
how it gets paid
Last year West Pharm made $3.1B in revenue. stoppers was the main engine at $1.18B, or 38% of sales.
why it's growing
Revenue grew 6.3% last year. The advance was likely driven by continued gains at both the proprietary products and contract manufactured products segments.
what just happened
The quarter looked huge on revenue, but the last tracked EPS print still missed by 1.62%.
At a glance
A balance sheet — strong enough to weather a downturn
70/100 earnings predictability — reasonably predictable
34.0x trailing p/e — you're paying up for this one
0.4% dividend yield — cash in your pocket every quarter
18.5% return on capital — nothing to write home about
xvary composite: 67/100 — average
What they do
West makes the stoppers, seals, and syringe parts that keep injectable drugs usable and sterile.
If your injectable drug goes into a vial or syringe, the tiny part still has to work every time. West turned $3.1B of revenue into a 29.0% operating margin in 2024, which tells you customers pay up for reliability. Foreign sales were 57% of 2024 revenue, so this trust is global, not local.
How they make money
$3.1B
annual revenue · their business grew +6.3% last year
stoppers
$1.18B
syringe components
$0.99B
seals
$0.56B
delivery systems and other
$0.37B
The products that matter
drug containment and delivery systems
Pharmaceutical Packaging & Delivery
$3.1B revenue
it's the entire $3.1B revenue engine. the page data shows 4.2% growth for this core segment, versus 6.3% for company-wide revenue, so the real question is mix — not whether West has another division waiting to bail it out.
the whole story
Key numbers
34.0x
trailing p/e
P/E → stock price divided by trailing profit per share → so what: you are paying $34 for each $1 of past earnings while projected earnings growth is 5.0%.
29.0%
operating margin
Operating margin → profit after running the business, before interest and taxes → so what: West keeps $0.29 from each sales dollar before financing costs.
18.5%
return on capital
Return on capital → profit earned on the money tied up in the business → so what: every $1 invested in operations generates about $0.185 in profit.
$203M
long-term debt
Long-term debt → money due after one year → so what: debt is just 1% of capital, which is unusually light for a $17B company.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 3 — safer than 50% of stocks
- price stability 45 / 100
- long-term debt $203M (1% of capital)
- net profit margin 20.3% — keeps 20 cents of every dollar in revenue
- return on equity 20% — $0.20 profit for every $1 investors have put in
A — among the top-rated companies for balance sheet quality.
Total return vs. market
You invested $10,000 in WST 3 years ago → it's now worth $9,000.
The index would have given you $14,770.
source: institutional data · total return
What just happened
missed estimates
The quarter looked huge on revenue, but the last tracked EPS print still missed by 1.62%.
EDGAR shows the latest quarter at $2.3B of revenue, up 182% vs. prior year, with EPS of $4.97 and gross margin of 35.3%. Separate consensus data shows the last reported EPS at $1.82 versus a $1.85 estimate, so the headline growth and estimate comparison are not telling the same story.
$2.3B
revenue
$4.97
eps
35.3%
gross margin
the number that mattered
The number that matters is 35.3% gross margin, because it shows West still has pricing power even while management says costs remain elevated.
-
west pharmaceutical services probably finished 2025 with solid results. (we note the company was scheduled to report numbers shortly after this issue went to press.) fourth-quarter sales increased 5%-7% compared to the previous-year tally.the advance was likely driven by continued gains at both the proprietary products and contract manufactured products segments. the former group may well have benefited from robust demand for high-value product components, including westar and envision stoppers. the latter division probably got a boost from higher volumes of selfinjection devices for obesity and diabetes. we think share earnings in the december quarter rose modestly, as the higher sales may well have been largely offset by elevated costs for labor and materials.
-
we anticipate solid top- and bottom-line growth in 2026.west ought to benefit from continued robust demand for high-value products and biologics components, especially for glp-1 and advanced drug systems.
-
we think industry destocking has abated somewhat and this should help support volume gains.share earnings should get a boost from operational efficiencies and a favorable pricing environment.
-
however, costs will probably remain elevated in the near term.tariff-related expenses are also expected to weigh on margins, but we think these will soften over time. we are initiating our 2027 top- and bottom-line estimates of $3.48 billion and $8.35 per share, respectively. the proliferation of biologics, higher glp-1 demand, and increasing regulatory requirements should help to support growth.
-
the balance sheet is also in good shape and cash flows are solid.these factors should allow the company to drive shareholder value through higher dividends and share buybacks. shares of west pharmaceutical are ranked to track the broader market averages in the coming six to 12 months.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is biologics and high-value component growth slowing while the stock still trades at 34.0x earnings.
high
the multiple assumes the good mix keeps getting better
West is priced like a durable growth supplier, not a generic packaging business. If biologics, GLP-1-related demand, or other high-value products slow down, the market has room to cut the premium.
34.0x earnings leaves little room for merely okay execution.
med
cost pressure can do more damage than it looks
the page calls out tariff-related expenses as a near-term issue. On paper, 17.1% net margin looks healthy. In practice, a margin squeeze on a single-core business gets noticed fast.
the current story depends on margins staying closer to the recent 17.1–17.4% range than slipping meaningfully below it.
med
there is no second engine in this snapshot
this page surfaces one core revenue line: $3.1B of pharmaceutical packaging and delivery. Focus is great when demand is clean. It is less fun when customers pause, destock, or push out orders.
a slowdown hits the same $3.1B revenue base that supports the whole equity story.
a slowdown in high-value products or a squeeze on that 17.1% net margin would hit a $3.1B revenue base and a 34.0x earnings multiple at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
whether margin stays near the recent 17% range
17.1% net margin for the year and 17.4% last quarter are the numbers holding the quality narrative together.
trend
signs that destocking is actually over
if customer inventories are normal again, reported growth should look cleaner from here. If not, the recovery story gets delayed again.
cal
the next quarter's mix in high-value products
management does not need heroics. It needs enough evidence that biologics and sophisticated components are still driving the better-margin mix investors expect.
risk
whether institutions keep buying after the bounce
369 buyers versus 327 sellers in 3q2025 is constructive. If that flips while fundamentals stay only decent, sentiment could fade faster than the business does.
Analyst rankings
short-term outlook
average
momentum score 3. in human-speak: analysts see a normal setup here, not a short-term breakout.
risk profile
average
stability score 3. This is neither a bunker stock nor a chaos stock.
chart momentum
average
technical score 3. The chart is behaving like the broader market, which means the thesis still has to come from the business.
earnings predictability
70 / 100
better than messy, worse than clockwork. You can model this business, but you should not expect zero surprises.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 369 buyers vs. 327 sellers in 3q2025. total institutional holdings: 69.1M shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$186
$408
$241
current price
$297
target midpoint · +23% from current · 3-5yr high: $540 (+125% · 23% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive